Cellular immunotherapy is showing promise as a new form of treatment that inhibits the various functions of cancer cells that enable them to evade the human immune system. In particular, thanks to improvements aided by the latest genome editing technology, CAR-T/TCR-T cell therapy is attracting attention as a treatment offering a decisive advantage against refractory cancer. However, as the cellular drugs covered by insurance are manufactured overseas, they have an extremely high price tag, making their widespread use among cancer patients impractical. Scientists say that the development of Japan’s own new generic technologies and license protection that do not rely on overseas intellectual property will need to be facilitated at the level of national government.